SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin to raise Rs 7,500 crore through various instruments

23 Jun 2015 Evaluate
Lupin is planning to raise around Rs 7,500 crore through various instruments either in domestic or overseas market or both. An enabling resolution seeking shareholders' nod for the fund-raising move will be placed at the forthcoming AGM next month.

The company’s board at its meeting on June 22 gave its approval in principle for raising of funds up to Rs 7500 crore by way of issue of securities i.e., equity shares, GDRs, ADRs, convertible bonds, equity linked instruments, etc. as may be appropriate. The enabling approval of the shareholders will be sought at the AGM to be held on July 23.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products.

Lupin Share Price

2398.70 2.20 (0.09%)
02-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1871.55
Dr. Reddys Labs. 1346.25
Cipla 1456.25
Zydus Lifesciences 1099.65
Lupin 2398.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: